Radiosensitization by BRAF inhibitors
| Autor: | Alexander Enk, Lisa Zimmer, Sophia Boyoung Strobel, Alexandra Jensen, Jessica C. Hassel, Sylvie Pätzold |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Proto-Oncogene Proteins B-raf Oncology Radiation-Sensitizing Agents medicine.medical_specialty Indoles Skin Neoplasms Combination therapy medicine.medical_treatment Medizin Dermatology 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Internal medicine Oximes medicine Humans Combined Modality Therapy Vemurafenib Melanoma Aged Neoplasm Staging Retrospective Studies Sulfonamides business.industry Cumulative dose Imidazoles Radiotherapy Dosage Dabrafenib medicine.disease Surgery Radiation therapy 030220 oncology & carcinogenesis Concomitant Disease Progression Female Radiodermatitis business medicine.drug |
| Popis: | Background Increased skin toxicity during combination therapy with a BRAF inhibitor and radiation therapy has recently been reported. Material and Methods We present seven melanoma patients with non-resectable stage III or IV disease and concomitant treatment with a BRAF inhibitor and radiation therapy. Results In all patients, combination therapy yielded a good local response. Only two patients, both on vemurafenib, showed severe radiation dermatitis (CTCAE grade 3/4) after one and two weeks, respectively, resulting in interruption of BRAF inhibitor treatment. The respective cumulative radiation dose was 10 Gy and 35 Gy. The remaining vemurafenib patients displayed only mild radiation dermatitis CTCAE grade 2; the only dabrafenib patient CTCAE grade 1. In one patient, recall dermatitis was diagnosed 14 days after completion of radiation therapy with a cumulative dose of 30 Gy. Conclusions Severe skin toxicity caused by BRAF inhibitor-induced radiosensitization is not common and usually amenable to treatment. Thus, combination treatment should remain a therapeutic option, especially in melanoma patients characterized by aggressive tumor growth. Although there is an increased risk of skin toxicity during combination therapy, it is usually well tolerated by most patients. Sequential – instead of simultaneous – treatment does not seem to prevent such toxicity reactions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|